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Abstract
Background: Cell-free fetal DNA sequencing based non-invasive prenatal testing (NIPT) for Down syndrome (DS) has
become widely available. In Hong Kong, obstetric providers in the public sector refer women identified at high risk of
having a child with Down syndrome to obstetric providers in the private sector for NIPT. Little is known about how the
NIPT has been adopted in the public sector where DS screening is provided for free of charge. The study aimed to
identify the factors influencing providers’ role enactment, such as consultation and referral, in the service provision of
NIPT for DS in public and private healthcare sectors.
Methods: In-depth interviews were conducted with 20 obstetric providers offering NIPT in Hong Kong. Thematic
narrative analysis was used to identify (i) the factors considered by participants when referring women for NIPT for
Down syndrome in public and private healthcare sectors and (ii) their perceptions of the need to integrate NIPT into
the current public antenatal service.
Results: Participants raised concerns about the lack of transparent referral guideline between public and private
sectors for NIPT. Public obstetric providers reported little obligation to provide women with much information
about risks and benefits of NIPT as it was not provided by public sectors. Some private providers assumed that
women referred from the public sector had already received sufficient information about NIPT. The providers
were also concerned about potential application of NIPT for further detection without regulation.
Conclusions: Although the providers had good knowledge of clinical advantages of NIPT over conventional
screening, they were uncertain about how to introduce NIPT to women. Guidelines are necessary to enable
better coordination of public and private sectors services to enable women to make informed choices about
the uptake of NIPT.
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Background
Non-invasive prenatal testing (NIPT) based on sequen-
cing cell-free fetal DNA in maternal plasma [1] has
marked increase in the accuracy of screening for Down
Syndrome (DS) in antenatal care settings. Research evi-
dence substantially reported that NIPT showed consist-
ent validity among the general and high-risk population,
with an overall higher sensitivity of 99.7% and lower of
0.04% [2] than the routine first trimester combined
screening (90% for a 5% false-positive rate) [3], which is
offered for free as a routine check-up in many countries
[4]. Based on the latest evidence of analytical and clinical
validity, professionals’ societies in obstetrics have recom-
mended NIPT as a primary screening for all pregnant
women regardless of age and risk status [5]. To exclude
false-positives, a positive NIPT result should always be
confirmed with invasive prenatal diagnoses (IPD), such
as amniocentesis or chorionic villus sampling that carry
a procedure-related risk of up to 1% [6]. Due to the ab-
sence of the procedural risk NIPT has become widely
available [7].
In prenatal testing, informed decision-making is essen-
tial to patient-centred care [8]. However, women may
not be sufficiently informed about DS screening during
the consultation, partly because obstetric care providers
prioritise the safety and validity of testing over women’s
needs and understanding of it [9]. The availability of
NIPT raises concerns about diminishing informed con-
sent. Obstetric providers report less need for consent
procedures for NIPT compared to IPD [10, 11], although
some women perceived NIPT as diagnostic testing [12].
Studies report women’s preference of deferring
decision-making to obstetricians with the assumption
that experts choose the best option for them [13]. The
roles of obstetric providers in the public sector are more
important in the consultation of NIPT because the test
is new, and women have to pay out of pocket. Women,
however, report little opportunity to discuss NIPT with
obstetric providers and report layman resources (e.g.,
press media, pamphlets by testing companies) as more
useful [7]. However, these resources provide selective in-
formation based on commercial interests and did not al-
ways meet clinical and ethical standards [14]. The
literature of clinical use of NIPT highlighted the critical
role by obstetric providers to ensure women receive ac-
curate information before test uptake.
Since the launch of NIPT in late 2011, studies have ex-
plored attitudes towards NIPT among obstetric providers
and patients [13, 15–21]. Overall, the providers reported
preference for NIPT over conventional DS screening due
perceived clinical advantages of lower numbers of
false-positive results and reduce maternal anxiety [11]. Im-
plementation of NIPT in the public health system of Hong
Kong, providing free DS screening and diagnosis is
challenging. NIPT has been rapidly adopted in practice;
for example, a private clinic reported about 80% antenatal
women chose NIPT [22]. A local study of 651 pregnant
women reported about two-thirds failed to distinguish
NIPT from diagnostic tests requiring confirmation of posi-
tive cell-free fetal DNA results [23]. It is unclear when and
how obstetricians working in the public sector need to
refer women for the privately available NIPT. Studies re-
ported that public sectors are constrained by a higher de-
gree of governing formalisation that limits the extent of
participation in the decision-making process with patients
[24], while private sectors place emphasis on economic re-
wards that healthcare services are observed as business
discourse [25]. Different organisational structures and
values in public and private sectors attribute to different
approaches to patient counselling and education [26].
Given the impact of service operationalisation on prac-
tices, the overall goal of the study was to understand the
factors influencing the obstetric providers’ role enactment
in the service provision of the novel NIPT for DS. In line
with the goal, the specific objectives of this study were to
explore (i) the factors considered by participants when re-
ferring women for NIPT for DS in public and private
healthcare sectors and (ii) their perceptions of the need to
integrate NIPT into the current public antenatal service.
Methods
The current study was part of a larger project to address
ethical and public health implications in the clinical im-
plementation of NIPT in Hong Kong. Using a sequential
explanatory mixed-methods design [27], the first phase
of a cross-sectional survey among DS screening pro-
viders assessed knowledge, attitudes and clinical experi-
ences of NIPT compared to conventional screening and
diagnosis. One of the significant findings was that ob-
stetric providers in public sectors reported significantly
more ethical concerns in the clinical implementation of
NIPT than private providers, including women’s in-
formed decision making, lack of consultation, unequal
access to NIPT, and unnecessary use of resource (e.g.,
multiple DS screening tests) [18]. The finding addressed
the importance of addressing system-level interventions
in facilitating informed choice for reproductive auton-
omy, effective coordination between public and private
sectors, and fairer resource allocation for better DS
screening techniques, including an option of introducing
NIPT in public antenatal care settings.
We subsequently developed a semi-structured
in-depth interview guideline to qualitatively explore
the findings from the quantitative phase and reasons
behind the discrepant attitudes focusing on the role
enactment among obstetric providers. Therefore, tak-
ing a qualitative approach, such as a phenomeno-
logical, narrative or grounded theory approach was
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deemed unnecessary. Instead, we used aspects of
grounded theory, for example, purposive sampling,
and saturation.
Sampling and recruitment
A sample of potential participants for the interview was
constructed from the survey respondents. They included
obstetric providers who drew blood for NIPT analysis or
referral for the service and those left their contact infor-
mation for a follow-up interview. Among 610 obstetric
providers invited, 327 returned the survey (response
rate: 53.7%), and 123 (34.5%) consented to be contacted
for the interview. We checked whether there were differ-
ences in demographics between those who agreed to be
contacted or not, and found no significant pattern sug-
gesting little concern for selection bias for the qualitative
study. A quota-sampling matrix was constructed to in-
vite participants for interview. This was based on profes-
sion (obstetrician and midwife), work sector (public and
private sector), and whether or not potential participants
provided NIPT. Simultaneous data collection and ana-
lysis enabled identification of emerging themes from the
outset. Using a purposive sampling framework, we in-
vited obstetric providers based on the study objectives
and demographics. The sampling method is designed to
maximise the variability of the sample in order to reach
saturation (i.e obtain a comprehensive understanding
until no new information is acquired), directing towards
the generation and development of conceptual theory as
opposed to creating a descriptive account [28]. In this
study, we reached data saturation of the key themes
around the seventeenth interview but decided to
complete twenty interviews to ensure inclusion of partic-
ipants according to our sampling matrix [29–31]. Writ-
ten informed consent was obtained from all study
participants. In-depth interviews were conducted in their
offices lasting from 45 to 90 min, and all were com-
pleted between July and August 2014. Ethical approval
was obtained from the joint university research ethics
committee and clinical research ethics committee in
Hospital Authority of Hong Kong.
Semi-structured interview
The interview guide was first developed based on a re-
view of the literature on NIPT and supplemented by the
quantitative findings. Local experts on NIPT reviewed
the questions to check whether the questions reflected
the current antenatal care systems in Hong Kong and
whether there were any leading questions. A pilot inter-
view was conducted among obstetricians and midwives
to ensure the language appropriateness. The final guide
consisted of questions and probes under the following
domains: (1) clinical experience of DS screening and
NIPT, for example how obstetric providers enact their
role in the consultation with pregnant women, (2) issues
arising from decision-making for NIPT, such as barriers
and challenges in consultation and referral, and (3) po-
tential integration of NIPT in public sectors. Table 1
shows sample interview questions.
All the interviews were conducted by the first author,
an experienced qualitative researcher who was inde-
pendent of the services in which the research was con-
ducted, hence not known to the study participants.
Having a single interviewer ensured consistency of the
interview process. Following each interview, the re-
searcher wrote memos reflecting on the interview
process and any interview questions that needed refining
or adding.
Data analysis
Interviews were digitally recorded, translated into Eng-
lish and transcribed verbatim. NVivo 10 software was
used to facilitate data storage, coding organisation, and
allocating categories systematically. Data analysis was
conducted using thematic narrative analysis [31] to
identify.
(i) the factors considered by participants when refer-
ring women for NIPT for Down syndrome in public and
private healthcare sectors and (ii) perception of the need
to integrate NIPT into the current public antenatal ser-
vice. Inductive analysis was conducted simultaneously to
identify emergent themes apart from the concepts of
role enactment. Transcripts were read repeatedly and
broken down into meaningful units of texts by the first
author. Codes were generated inductively by analysing
content domains that emerged from the narratives, and
codes were then clustered to form broader categories for
presentation in the paper. These categories were further
refined through member-checking by the research team
Table 1 Sample interview questions
1. Clinical experience of Down syndrome screening and NIPT
• How do you introduce NIPT to women?
• When you provide consultation on NIPT for women, how did
women respond?
• How do you find your clinical experience using the NIPT, compared
to the current first-trimester screening and invasive prenatal
diagnosis?
2. Issues arising from decision-making For NIPT
• What aspect of NIPT would women consider the most important?
• Have you encountered any difficulties in the consultation? If so,
what’re the barriers?
3. Potential integration of NIPT in public sectors
• Since the introduction of NIPT in your clinic, what changes have you
observed in prenatal care?
• What is your opinion about integrating NIPT in the universal
screening pathway?
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members who have extensive expertise in qualitative
health services research in this field. Additionally, to en-
hance the credibility of our interpretation of the findings,
the first and second author regularly discussed the inter-
viewer’s reflections on the interview process, and any per-
sonal assumptions and preconceptions, which may
influence participants’ responses about genetic testing, ter-
mination of pregnancy, disability, parenting, and family.
Results
Our study sample was diverse: 5 were male; 8 were
obstetricians, and 12 were midwives; 13 worked in pub-
lic sectors, and 13 provided referral and 7 performed
blood draw for NIPT. The average years of obstetric
practices were 13.3 years (SD = 9.1, range: 2–30 years)
and provided NIPT service was 2.2 years (SD = 0.9 years,
range: 1–4 years). Further details of the demographics of
participants are shown in Table 2.
We have identified four major thematic categories fol-
lowing analysis: (1) perceptions of information to facili-
tate women’s decisions about NIPT; (2) perceptions of
clinical guidance needed on referral for NIPT; (3) private
providers’ assumptions about the provision of public
pre-test information for NIPT; and (4) perceptions of
equitable access to NIPT.
Perceptions of information to facilitate women’s decisions
about NIPT
In the consultation on prenatal screening, the obstetric
providers said that they mostly focused on clinical and
procedural aspects of testing. They did not discuss the
options available after screening such as termination of
pregnancy (TOP) and health conditions of the affected
unborn baby, which they consider as topics of
pre-counselling for IPD. This principle was applied simi-
larly to NIPT. Participants confirmed that the informa-
tion they provided about NIPT was mainly factual,
including NIPT being a blood test, its sensitivity, no risk
of miscarriage, test limitations and the conditions
screened. None of the participants believed the topic of
TOP was essential pre-test information for NIPT, be-
cause they considered ‘NIPT is no more than screening’
and TOP as too sensitive to discuss at this stage.
We would not mention the term, termination of
pregnancy explicitly but frame it in this way, like
‘would you like to continue the pregnancy or to have
other thoughts?’ (midwife, public).
Participants said that women found to be at
high-risk following screening often asked them for









1 m/ ≥ 51 Tertiary Obstetrician Private Blood Draw 30 3
2 f/ ≤ 30 High School Clinic Nurse Private Blood Draw 3 2
3 f/ 31–40 Tertiary Midwife Public Referral 9 2
4 f/ 31–40 Tertiary Obstetrician Public Referral 8 2
5 f/ 41–50 > Master Midwife Public Referral 20 3
6 m/ 41–50 > Master Obstetrician Public Referral 24 3
7 m/ 41–50 Tertiary Obstetrician Private Blood Draw 20 4
8 f/ 31–40 Tertiary Obstetrician Public Referral 7 2
9 f/ ≥ 51 Tertiary Midwife Public Referral 20 1
10 m/ 31–40 Tertiary Obstetrician Public Referral 10 2
11 f/ ≥ 51 Tertiary Clinic Nurse Public Referral 2 1
12 f/ ≤ 30 ≥ Master Midwife Public Referral 3 2
13 f/ 41–50 Tertiary Midwife Public Referral 20 1
14 f/ 41–50 ≥ Master Midwife Public Referral 25 3
15 f/ ≤ 30 High School Clinic Nurse Private Blood Draw 9 1
16 f/ 41–50 ≥ Master Midwife Private Blood Draw 20 2
17 m/ 41–50 Tertiary Obstetrician Public Referral 23 3
18 f/ ≤ 30 Associate Clinic Nurse Private Blood Draw 3 3
19 f/ ≤ 30 High School Clinic Nurse Private Blood Draw 5 3
20 f/ ≤ 30 Tertiary Obstetrician Public Referral 4 1
f = female, m = male
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advice about NIPT, ‘should I take it or not?’ Partici-
pants explained that they were reluctant to give advice
or engage in discussion about NIPT, particularly those
from public sectors, because the decision to opt for
NIPT should be the women’s. Participants often used
terms such as ‘up to them’ and ‘their free choice’ im-
plying their understanding of being able to influence
women, hence hesitance to get involved in the
decision-making process by avoiding discussion of
NIPT:
My duty is to inform her with factual information
about advantages and disadvantages of each test. We
do not want to involve making a decision for private
service with patients but give them liberty. (midwife,
public).
Reluctance to discuss information about NIPT also
appeared to be due to perceptions of their own lack
of knowledge about cell-free fetal DNA sequencing
technology. Obstetricians mostly obtained the infor-
mation through scientific reports while midwives and
clinic nurses primarily relied on informal training
provided by workplaces, such as verbal informants
and leaflets. Participants explained feeling unprepared
to answer ‘hard questions’ from women:
Our level of understanding of NIPT is limited and
very simple. I am afraid that women would not be
able to receive proper information until they walk into
the room and see a doctor. (clinic nurse, private).
Many participants in public sectors were concerned
about providing information that may influence women’s
decision. They understood the importance of providing
more factual information to support women’s
decision-making but were concerned that more in-depth
conversations about NIPT could influence them. Also,
while informing women about NIPT was considered im-
portant, participants acknowledged time constraints in
public sectors and that NIPT was only available in pri-
vate sectors, highlighting the issues arising from the
overlap of public and private service provision:
NIPT is not part of the universal prenatal screening
program. Unlike the private sectors that offer a test
and incur a charge of consultation on women, time
does not allow us [public providers] to give detailed
consultation on prenatal screening for everyone.
(obstetrician, public).
Participants also explained that in conversation with
pregnant women, they explore personal values and un-
derstandings of NIPT, but time constraints hindered
in-depth discussions on NIPT in public services. This
lack of information relates to participants concerns
about the lack of regulations in the use of NIPT in the
private sector:
If women have access to commercial laboratory-based
genetic test without a referral, I doubt whether labora-
tories have designated accredited persons to ensure
women’s autonomy by full comprehension on testing
procedure and outcomes, and their implications in
their life. (obstetrician, public).
A provider in private sectors commented:
The laboratory is an analysis site that does not include
consultation provided by doctors. Test analysis site
requires a person to oversee, read, and interpret a
report. I would be concerned if women left
uninformed. (clinic nurse, private).
Participants envisioned that advance in DNA sequen-
cing would lead to the availability of testing for an in-
creasing number of genetic conditions, but worried
about the insufficient availability of genetic counselling
to enable women to understand the implications of test
results and support subsequent decision-making:
Genetic technology has advanced quickly from basic
research to clinical trials and commercialisation. It
has dangerously left doctors unprepared for handling
the broader scope of health conditions that can be
detected by NIPT. In the local context we have
insufficient counselling experts, we doctors are
responsible for counselling, despite our
unpreparedness. (obstetrician, public).
Perceptions of guidance needed on the referral for NIPT
The current local health authority guidelines on DS
screening do not specify the use of NIPT on the
prenatal screening pathway. Participants believed that
this further introduced challenges in the provision of
antenatal care and confusion about the roles and re-
sponsibilities of healthcare professionals in public and
private sectors:
The local authority has not yet addressed the use
of NIPT under the existing system. We, public
providers, were also lost. We did not know what to
do with a referral. Many clinicians are offering
NIPT. They may approach the test differently. I do
not know how they do. I am concerned that
patients fail to receive the testing service in a
standard way. (obstetrician, public).
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Furthermore, public providers gave specific details on
the challenges, for example, who would be offered NIPT.
The cut-off ratio for high-risk varies by laboratories and
clinics. Clinicians had a different interpretation of risk.
The high-risk cut-off from routine screening ranges
from 1:250 to 1:270. It highly depends on how a doc-
tor interprets the result as understanding the idea of
‘risk’ differs. For example, would you refer a woman
with a result of 1:251 to take an additional test, al-
though she does not fall into ‘abnormal’ category, yet
far from ‘safe’ zone? It varies across obstetricians. (ob-
stetrician, public).
Participants said that many women asked a question
about how NIPT was acknowledged in public services of
prenatal testing and sought an opinion about which test
among those available privately they should undergo.
Public providers found it challenging to deliver neutral
counselling and provide information in the absence of
guidelines from the local public health authority.
Even after giving out all test information, women did
not apprehend and wanted to seek a directive,
actionable suggestion from me. They often asked me
‘what would you do in my position? I do not
understand the options here.’ I felt challenged that I
do not know how to respond and where should I refer
to? (midwife, public).
Their advice was then that women should contact pri-
vate clinics hoping that women would eventually receive
comprehensive information about NIPT.
Private providers’ assumptions about the provision of
public pre-test information for NIPT
Unlike obstetric professionals in public services referring
women for NIPT, obstetric professionals in private ser-
vices providing NIPT showed more diverse opinions
about NIPT. Two types of service approaches were
found. Some private providers assumed that if a woman
made a booking for NIPT with referral via public sec-
tors, she must have had sufficient information to make
an informed decision:
If a woman [from the public] calls and give explicit
instructions for scheduling an appointment for NIPT,
I would proceed to appointment booking directly. I
would not provide the test information for those
women unless they enquired what test they should
take. (clinic nurse, private).
On the other hand, some private providers believed it
was important to ensure women were making informed
decisions about NIPT and, therefore, not to make any
assumptions about information that may have already
been provided or women’s understandings of this
information:
Whether women come with or without a referral, we
must reiterate the purpose of their visit and discuss
testing options with them from the beginning. They
receive clearer and better information from us than
public sectors before meeting our doctor. (clinic
nurse, private).
In addition to prior screening history and risk indica-
tors, pre-test discussions by private providers covered
the cost of NIPT. Participants explained that when there
was no financial constraint for women, they preferred
this test due to its higher test accuracy.
I would explain to women the price of each screening
test and subsequent cost if the result is positive. The
conventional screening is cheaper than NIPT.
However, women could save more money if women
take NIPT directly as primary screening in the first
place. Taking NIPT as a contingent test upon
receiving a positive test result would cost more money
and time. (clinic nurse, private).
Private providers’ views towards informed consent
were similar to their public counterparts – screening in
no need for going in detail. Notably, some private pro-
viders said that taking NIPT as a secondary test, after
negative result DS screening would not need a full in-
formed consent procedure as they believed that the pri-
mary purpose of NIPT is psychological assurance.
Many women do not have questions, and just take a
look at the consent form and give their signature.
Probably, most laymen would think it is fine as long
as the test provides them with an assurance and
reduces their anxiety. (clinic nurse, private).
Perceptions of equitable access to NIPT
The participants commented on scarce resources in the
public antenatal care setting and acknowledged the vital
role of private sectors in service delivery. Participants
believed that the main reasons for women’s uptake of
private services in addition to public services included
the failure of timely access to public antenatal care and
for reassurance. Accordingly, participants suggested that
NIPT addressed needs:
Paying out of pocket for NIPT may be costly but
very meaningful for women who missed the first-
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trimester tests and limited to second-trimester
screening only. I learnt from my obstetric colleague,
who was also a pregnant woman that the feeling
after being reassured for abnormality-free results
from routine screening and NIPT could be very sub-
stantial. (obstetrician, public).
Participants also highlighted that multiple visits to
both public and private services for cross-monitoring
(known as ‘doctor shopping’) was not uncommon in
Hong Kong. They observed women who had taken
NIPT, also opting for DS screening in public services,
where they know the latter has lower accuracy. Such up-
take of multiple screenings was believed to result in un-
necessary screening and, hence, spending of scarce
public healthcare resources. Some participants also
raised ethical concerns about the high cost of NIPT,
hence its availability only to those who could afford it.
Participants believed the overlap between public and pri-
vate services lead to an unjust healthcare service where
less privileged women did not have equitable access to
NIPT as a reassuring test and instead had to opt for tests
with a risk of miscarriage:
NIPT is expensive. I believe that the public healthcare
system cannot afford to support the cost of NIPT for
every woman. How many ordinary families could
afford this test without receiving a subsidy from the
government? As a consequence, only rich people can
take this test while others cannot afford the test and
suffer more. (obstetrician, public).
A consensus among participants was prevalent that
without proper regulations facilitating better integration
of NIPT, the gap between public and private sectors was
likely to widen.
Discussion
The study identified the factors influencing their role en-
actment in the consultation and referral regarding the
service provision of NIPT for DS in public and private
healthcare sectors, including information for decision
making, guide of referral for NIPT from public to private
sectors, private sectors’ assumption and stance of NIPT
pre-testing information before referral, and concerns
about equitable access to NIPT. The lack of standard
care was found to be related to not only the characteris-
tics of a laboratory-private test but also the participants’
view that NIPT is similar to routine screening [32]. They
used the same degree of informed consent procedure for
DS screening in NIPT holding an opinion that a detailed
discussion is unnecessary [10]. As the result of NIPT has
no direct implication on whether the pregnancy would
be continued or terminated, the obstetric providers in
public sectors would not feel the need for the use of
their scarce resource (e.g., time, information, and
communication) to enhance the quality of NIPT service.
This raises two important questions concerning the pur-
pose of informed consent and informed decision-making
for NIPT.
The goal of prenatal testing is to enhance reproductive
autonomy, which is safeguarded by informed consent
enabling women to fully understand the purpose, proce-
dures, risk, and benefits of the test [33]. Discussion of
TOP is only part of informed consent that covers
women’s knowledge, norms, and values. However, the
majority of providers in the study justified the depth of
informed consent based on whether there should be a
discussion on TOP or not; if no discussion on TOP, in-
formed consent can be simple. This outcome-based in-
formed consent disregards the real reasons for women
to undergo the test – to know the condition of the un-
born baby. Such an approach to informed consent is ra-
ther paternalistic as it ignores a core principle of
whether or not a woman wants to discuss, not of
whether or not TOP should be discussed. Some women
prefer to discuss TOP after receiving the confirmation
by IPD as early discussion would induce psychological
distress, but some women prefer to discuss at an early
stage. Withholding the discussion might undermine
women’s capacity to recognise her choice of screening at
the time of the decision-making.
While the literature on ethical issues of NIPT ad-
dresses the erosion of informed consent due to the eases
related to the test [33], it fails to address the issue of re-
ferral between public and private sectors and how this
relates to health professionals responsibility to ensure
patients are making autonomous decision [34]. One of
the salient themes in this qualitative study was providers’
reluctance to engage in decision-making for prenatal
testing. Furthermore, nondirective counselling is recom-
mended by obstetric professional societies [35]. A study
with obstetric providers and patients in the United
States found that the nondirective approach was deliv-
ered by an emphasis of ‘screening is optional’ and nor-
malisation of screening ‘other women choose as well’
[36]. The study also noted that lack of in-depth discus-
sions on prenatal screening was prevalent between pro-
viders and patients and therefore a lack of patient
understanding was reported. Another qualitative study
in Hong Kong also found that providers often delineated
their roles and constructed their professional identity as
a non-directive information provider [37].
There is an ethical dilemma that the ethos of ‘it is the
patient’s choice’ often leaves pregnant women isolated
and unsupported to make informed choices [38]. Sup-
porting women to make informed choices about prenatal
screening tests is especially important to address in
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countries with two-tiered healthcare systems, where the
likelihood of women receiving information and profes-
sional support for decision-making from either is low.
Public providers only offer tests subsidised by public
funding but may feel morally responsible for informing
pregnant women about the availability of public tests to
provide a ‘better’ antenatal service. Further research is
needed to devise a culturally appropriate informed
decision-making guideline for NIPT specific to the
healthcare system [39, 40]. Our finding shows that there
is a need for guidelines for public services on making re-
ferrals to private services, to provide an optimal ante-
natal service for all women.
There are practical reasons for the need of guidance.
Since NIPT was first commercially launched in late 2011,
professional societies’ policy and recommendations have
been changed according to scientific evidence. Several
countries currently consider widening access of NIPT sub-
sidised by the national funding. In the UK, the National
Health Service (NHS) intends to incorporate it as a con-
tingent screening test in a publicly funded program for all
women screened high-risk from first-trimester screening
starting from 2018 [41]. In the Netherland, the Health
Council plans to adopt the test for all pregnant Dutch
women [42]. Meanwhile, the advance of cell-free fetal
DNA sequencing technology is expanding gene panels to
detect a broader range of fetal conditions. Commercial
companies offer NIPT for conditions, including sex
chromosome aneuploidy and a few micro-deletions
syndrome, despite the limited of robust evidence and as-
sessment of risk-benefit [43]. In response to these devel-
opments, the national framework or regulatory guideline
of NIPT is essential for the quality care and patient safety
reflecting societal norms and healthcare system [44].
There were different patterns of responding to the
issue of affordability of NIPT. In private sectors, if
women were found to afford the test, NIPT was rec-
ommended as it would shorten the clinical pathway
for DS diagnosis and might reduce pregnancy-related
anxiety. In public sectors, the providers often faced a
question of whether they should refer a woman to a
better option of NIPT in private sectors and in doing
so how they engage in discussions about the benefits
over the cost. This relates to a concern about fair
treatment. In ethics of distributive justice, unequal ac-
cess to medical intervention is permissible if patients
are not harmed significantly without it. For example,
although the quality of public education might not be
good as, perhaps poorer than, private education, we
would not say public education system is unjust. The
current DS screening in Hong Kong has a rigorous
internal and external quality assurance programme
that identifies 93% DS affected pregnancies suggesting
using NIPT as primary screening may be redundant
and surplus of antenatal care resources [45]. However,
for the justice issue of women in public sectors not
being harmed more than those in private, NIPT needs
to be introduced in public sectors to reduce the fetal
loss by IPD procedure. For ‘low-risk’ women, the con-
sultation and informed consent for DS screening need
to be enhanced as it plays a critical role in ensuring
women’s autonomy and reduce maternal anxiety.
Limitations and strengths
There are several limitations. The study did not assess
the degree of participants’ knowledge and views of NIPT,
which might be associated with perceived barriers to
providing the test. The study did not explore institu-
tional policy aspects of NIPT by interviewing the
hospital managers. Further studies among other stake-
holders are needed. Nevertheless, our study highlights
important points that could inform policy development
about the integration of NIPT within public services in
HK and other countries.
Conclusions
NIPT is a good example of why the public and private
sectors should work together to improve quality care for
women. As one of the most rapidly introduced and
widely used out-of-pocket tests, many countries are
under consideration of introducing it into the public
healthcare system for pregnant women who are deemed
at high risk for DS. The potential conflicts of roles and
responsibilities in public and private sectors have been
observed – how the healthcare system and organisa-
tional factors influence the enactment of obstetric pro-
viders’ role in the consultation of NIPT. In response to
policy discussion of clinical adoption, it is necessary to
minimise the discrepancy in knowledge and attitudes of
NIPT between the sectors by providing continuing med-
ical education on the advance of cell free fetal DNA se-
quencing technologies and standardised protocol of
NIPT procedure, enacting a clear referral and counsel-
ling guideline, and establishing monitoring system for
quality assurance across the sectors. Not all pregnant
women are eligible to receive publicly subsidised NIPT
and there are many laboratory companies offering the
test at varying costs. Thus, the development of practice
guideline is essential to enable better coordination NIPT
between the two sectors services to enable women to
make informed choices about the uptake of NIPT pri-
vately. Such guidelines should not be drawing the
boundary between two sectors but how they should col-
laborate, especially how private sectors can supplement
the limited resources in public sectors to fill the gaps
and address the needs of pregnant women.
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